ERBB2 and breast cancer: Integrating p53 status determined by IHC with the traditional clinicopathological features in patients with HR-positive/Her2-negative breast tumors can be a valuable tool in the hands of the clinician in the decision of the most appropriate therapy, particularly in patients with early breast cancer and null p53 expression.